InMode (NASDAQ:INMD) updated its FY 2021 earnings guidance on Monday. The company provided EPS guidance of $3.100-$3.250 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.960. The company issued revenue guidance of $305 million-$315 million, compared to the consensus revenue estimate of $292.45 million.InMode also updated its Q2 2021 guidance to $1.000-$1.010 EPS.
A number of research analysts have commented on the stock. Canaccord Genuity upped their target price on shares of InMode from $95.00 to $120.00 and gave the company a buy rating in a research report on Thursday. Barclays upped their target price on shares of InMode from $92.00 to $120.00 and gave the company an overweight rating in a research report on Tuesday, July 13th. Needham & Company LLC upped their target price on shares of InMode from $119.00 to $129.00 and gave the company a buy rating in a research report on Thursday. Zacks Investment Research cut shares of InMode from a strong-buy rating to a hold rating in a research report on Tuesday, April 13th. Finally, Robert W. Baird upped their target price on shares of InMode from $84.00 to $104.00 and gave the company an outperform rating in a research report on Thursday, May 6th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. InMode has an average rating of Buy and a consensus target price of $106.00.
Shares of INMD traded up $2.00 during mid-day trading on Monday, hitting $115.67. 8,525 shares of the company’s stock were exchanged, compared to its average volume of 724,093. The company has a market capitalization of $3.70 billion, a P/E ratio of 37.89 and a beta of 1.87. InMode has a fifty-two week low of $29.15 and a fifty-two week high of $117.39. The company has a 50-day moving average of $96.18.
InMode (NASDAQ:INMD) last issued its quarterly earnings results on Wednesday, July 28th. The healthcare company reported $1.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.54. InMode had a net margin of 44.34% and a return on equity of 45.87%.
About InMode
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.
Featured Story: What is the role of the G-20?